Cargando…
PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
BACKGROUND: Despite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to SARS-CoV-2 infection by virtue of underlying health conditions, treatments received or suboptimal responses to vaccination....
Autores principales: | Humphrey, Toby J. L., Dosanjh, Davinder, Hiemstra, Thomas F., Richter, Alex, Chen-Xu, Michael, Qian, Wendi, Jha, Vivekanand, Gatley, Katrina, Adhikari, Rakshya, Dowling, Francis, Smith, Rona M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009350/ https://www.ncbi.nlm.nih.gov/pubmed/36915199 http://dx.doi.org/10.1186/s13063-023-07128-z |
Ejemplares similares
-
D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial
por: Franssen, Marloes, et al.
Publicado: (2021) -
RECAST: Study protocol for an observational study for the understanding of the increased REsilience of Children compared to Adults in SARS-CoV-2 infecTion
por: Stricker, Sebastian, et al.
Publicado: (2023) -
A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients – the HEALTHY-CATH trial
por: Broom, Jennifer K, et al.
Publicado: (2012) -
Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients
por: Broom, Jennifer K, et al.
Publicado: (2009) -
497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial
por: Dosanjh, Davinder, et al.
Publicado: (2023)